Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
NCT06433609Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Aug 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, tizetatug rezetecan, SHR-A2102, adebrelimab in breast cancer, sponsored by Beijing Gaobo Hospital. Started Aug 2024; status: recruiting.
02
Drugs
trastuzumab rezetecantizetatug rezetecanSHR-A2102adebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06433609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433609.